From Preclinical Promise to Human Proof: Kioga Bio’s Early Commitment to Clinical Validation

Kioga Bio entered the Alethios Early Stage Program with a clear conviction: if their science was going to meaningfully improve immune regulation and mental resilience, it needed to be validated in humans — not just in models. Rather than waiting for ideal financing conditions, the team chose to generate rigorous clinical evidence early. Co-Founder Adam Bohr reflects on breaking the startup data paradox, executing a randomized controlled trial as a small team, and why human validation can’t be an afterthought.

1. Briefly describe Kioga Bio’s mission and the human health problem you’re working to solve.

Adam Bohr:
Kioga reintroduces environmental bacteria that have been removed from modern living. These bacteria, which we co-evolved with for millennia, have largely been lost to us. The consequences are immune dysregulation, chronic inflammation, and impaired mental well-being. Our goal is to restore what modern environments have stripped away.

2. When you were early-stage, what were the biggest barriers to generating credible human evidence?

Adam Bohr:
Money. We faced the classic startup paradox: we needed human data to attract financing, and we needed financing to generate human data. Without funding, it was impossible to spend hundreds of thousands of dollars on a traditional CRO. We had the expertise internally to design the study, but we needed infrastructure and access to participants to execute it.

3. What motivated you to run human studies earlier than many ingredient or biotech companies typically do?

Adam Bohr:
Our entire company mission is based on decades of scientific research. The natural progression of that science was to run a clinical trial. Many products don’t translate from preclinical models into meaningful human effects, and we weren’t willing to bring something to market unless we knew it truly worked.

4. What was the first study you ran using Alethios, and what question were you trying to answer?

Adam Bohr:
Our first study was a randomized, double-blind, placebo-controlled clinical trial. We wanted to confirm that the stress resilience benefits we observed in preclinical models would translate into measurable benefits in daily human use.

5. How did you decide on the study design and endpoints?

Adam Bohr:
Much of our design was informed by the rigor of prior NIH-funded trials our team had conducted in other disciplines. Alethios made it easy to implement endpoints at multiple timepoints and with greater frequency than we likely would have used in a centralized trial.

6. What surprised you most about running decentralized human studies as a small team?

Adam Bohr:
The speed of enrollment. I was genuinely surprised by how quickly we were able to recruit a representative sample. Alethios’ recruiting methods kept a steady stream of potential participants coming in every day.

7. How did the results inform product development, partnerships, or fundraising decisions?

Adam Bohr:
The results clarified how we want to design our next studies. With additional financing, we’re now prepared to incorporate more objective measures — particularly wearables and biomarkers — to further validate the product and strengthen our position.

8. What did running one study enable you to do differently or better in the next?

Adam Bohr:
It gives us confidence and execution speed. We initially had uncertainty around recruitment and enrollment. Now we know we can execute a bold trial. We also identified areas where we kept too much in-house — and in future studies, we would lean more heavily on Alethios to streamline the process.

9. What does graduating from the Alethios Startup Program mean for Kioga Bio at this stage?

Adam Bohr:
It gives us instant industry credibility. It shows we are committed to rigorous clinical validation and capable of executing it.

10. What advice would you give to another early-stage team considering their first human study?

Adam Bohr:
There’s no point in waiting. Human data is no longer optional — it’s becoming essential. And with the right partners and a willingness to understand clinical methods, you can execute a rigorous study more affordably than you might think.

Kioga Bio’s journey underscores a broader shift in health innovation: serious science demands serious human validation — and the most forward-thinking teams are building that foundation from day one.

‍